CombiGene (LARK.ST) Stock Analysis & AI Equity Report
CombiGene (LARK.ST) overview
CombiGene (LARK.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, CombiGene reported revenue of SEK 0.3m and operating profit of SEK -47.2m; the year-end share price was 2.38 SEK and market capitalisation was SEK 47.1m. CombiGene is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CombiGene's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About CombiGene
CombiGene AB (publ) is a Swedish biotechnology company focused on gene therapy and other advanced treatments for severe diseases. Its business model has centred on identifying promising assets, advancing them to proof of concept, and outlicensing them to partners for continued development and commercialization. In January 2025, it announced discontinuation of research activities.
Generate the CombiGene report
CombiGene is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CombiGene and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.